Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PHIBRO ANIMAL HEALTH CORPPAHC · Entity 4671 | Director · President and CEO | August 06, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PHIBRO ANIMAL HEALTH CORP
Report date August 06, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 15,177 |
Reported balance
After 2026-08-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-06 · Grant · Acquired 11,699 · Balance 15,177 F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.
F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 10, 2026 20:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | GrantClass A Common Stock | 11,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-093378 · tm2622592-1_4seq1.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,177 F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date. Read SEC document |
| August 04, 2026 Filed Aug 7, 2026 00:10 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | OtherClass A Common Stock | 486 | $36.60 | $17,787.11 |
DisclosureSEC source: 0001104659-26-092227 · tm2622506-1_4seq1.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,478 F1 · shares: Represents shares sold in a broker assisted cashless exercise program to satisfy tax withholding obligations upon the receipt of Class A Common Stock in connection with the vesting and settlement of restricted stock units. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:15 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | GrantPerformance Stock Units · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-080332 · tm2619107-1_4seq1.xml · derivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Class A Common Stock · 300,000 shares Expires 2031-06-30 F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of Class A Common Stock. F2 · derivative.exercise_date: The PSUs shall vest (or be forfeited), in full or in part, on June 30, 2031, subject to achievement of specified stock price performance measured as of, and subject to the Reporting Person's continued employment on, such date. F2 · derivative.expiration_date: The PSUs shall vest (or be forfeited), in full or in part, on June 30, 2031, subject to achievement of specified stock price performance measured as of, and subject to the Reporting Person's continued employment on, such date. F2 · derivative.underlying_shares: The PSUs shall vest (or be forfeited), in full or in part, on June 30, 2031, subject to achievement of specified stock price performance measured as of, and subject to the Reporting Person's continued employment on, such date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:17 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | GrantClass A Common Stock | 3,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-080266 · tm2523826-4_4seq1.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,964 F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to the Reporting Person's continued employment through the applicable vesting date. Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 02:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,390 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-003872 · tv511990_4.xml · derivative · entry 9 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,390 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 02:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,390 | $31.15 | $74,448.50 |
DisclosureSEC source: 0001144204-19-003872 · tv511990_4.xml · nonDerivative · entry 6 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.04 to $31.30, inclusive. Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 02:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,390 | $11.83 | $28,273.70 |
DisclosureSEC source: 0001144204-19-003872 · tv511990_4.xml · nonDerivative · entry 5 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 02:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 4,890 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-003872 · tv511990_4.xml · derivative · entry 8 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,390 Underlying: Class A Common Stock · 4,890 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 02:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 4,890 | $31.32 | $153,154.80 |
DisclosureSEC source: 0001144204-19-003872 · tv511990_4.xml · nonDerivative · entry 4 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.08 to $31.73, inclusive. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 02:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 4,890 | $11.83 | $57,848.70 |
DisclosureSEC source: 0001144204-19-003872 · tv511990_4.xml · nonDerivative · entry 3 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 28, 2019 Filed Jan 31, 2019 02:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-003872 · tv511990_4.xml · derivative · entry 7 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,280 Underlying: Class A Common Stock · 2,500 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 28, 2019 Filed Jan 31, 2019 02:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,500 | $31.55 | $78,875.00 |
DisclosureSEC source: 0001144204-19-003872 · tv511990_4.xml · nonDerivative · entry 2 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.19 to $32.08, inclusive. Read SEC document |
| January 28, 2019 Filed Jan 31, 2019 02:07 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-19-003872 · tv511990_4.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 02:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-002703 · tv511485_4.xml · derivative · entry 10 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,780 Underlying: Class A Common Stock · 2,500 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 02:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,500 | $31.78 | $79,450.00 |
DisclosureSEC source: 0001144204-19-002703 · tv511485_4.xml · nonDerivative · entry 7 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.10, inclusive. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 02:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-19-002703 · tv511485_4.xml · nonDerivative · entry 6 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 02:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-002703 · tv511485_4.xml · derivative · entry 9 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,280 Underlying: Class A Common Stock · 2,500 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 02:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 590 | $32.18 | $18,986.20 |
DisclosureSEC source: 0001144204-19-002703 · tv511485_4.xml · nonDerivative · entry 5 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.13 to $32.21, inclusive. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 02:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,910 | $31.58 | $60,317.80 |
DisclosureSEC source: 0001144204-19-002703 · tv511485_4.xml · nonDerivative · entry 4 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $32.07, inclusive. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 02:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-19-002703 · tv511485_4.xml · nonDerivative · entry 3 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 02:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-002703 · tv511485_4.xml · derivative · entry 8 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,780 Underlying: Class A Common Stock · 2,500 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 02:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,500 | $31.40 | $78,500.00 |
DisclosureSEC source: 0001144204-19-002703 · tv511485_4.xml · nonDerivative · entry 2 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.15 to $31.82, inclusive. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 02:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-19-002703 · tv511485_4.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 18, 2019 Filed Jan 19, 2019 02:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-002146 · tv511196_4.xml · derivative · entry 10 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,280 Underlying: Class A Common Stock · 2,500 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 18, 2019 Filed Jan 19, 2019 02:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,500 | $32.04 | $80,100.00 |
DisclosureSEC source: 0001144204-19-002146 · tv511196_4.xml · nonDerivative · entry 6 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.88 to $32.19, inclusive. Read SEC document |
| January 18, 2019 Filed Jan 19, 2019 02:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-19-002146 · tv511196_4.xml · nonDerivative · entry 5 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 17, 2019 Filed Jan 19, 2019 02:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 110 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-002146 · tv511196_4.xml · derivative · entry 9 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,780 Underlying: Class A Common Stock · 110 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 17, 2019 Filed Jan 19, 2019 02:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,390 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-002146 · tv511196_4.xml · derivative · entry 8 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,390 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 17, 2019 Filed Jan 19, 2019 02:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,500 | $32.24 | $80,600.00 |
DisclosureSEC source: 0001144204-19-002146 · tv511196_4.xml · nonDerivative · entry 4 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.09 to $32.42, inclusive. Read SEC document |
| January 17, 2019 Filed Jan 19, 2019 02:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-19-002146 · tv511196_4.xml · nonDerivative · entry 3 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 16, 2019 Filed Jan 19, 2019 02:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-002146 · tv511196_4.xml · derivative · entry 7 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,390 Underlying: Class A Common Stock · 2,500 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 16, 2019 Filed Jan 19, 2019 02:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,500 | $32.40 | $81,000.00 |
DisclosureSEC source: 0001144204-19-002146 · tv511196_4.xml · nonDerivative · entry 2 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.13 to $32.51, inclusive. Read SEC document |
| January 16, 2019 Filed Jan 19, 2019 02:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-19-002146 · tv511196_4.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-001393 · tv510834_4.xml · derivative · entry 6 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,890 Underlying: Class A Common Stock · 2,500 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,500 | $32.54 | $81,350.00 |
DisclosureSEC source: 0001144204-19-001393 · tv510834_4.xml · nonDerivative · entry 4 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-19-001393 · tv510834_4.xml · nonDerivative · entry 3 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 08, 2019 Filed Jan 11, 2019 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-001393 · tv510834_4.xml · derivative · entry 5 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,390 Underlying: Class A Common Stock · 2,500 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 08, 2019 Filed Jan 11, 2019 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,500 | $32.31 | $80,775.00 |
DisclosureSEC source: 0001144204-19-001393 · tv510834_4.xml · nonDerivative · entry 2 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 08, 2019 Filed Jan 11, 2019 02:14 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-19-001393 · tv510834_4.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 01:08 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-000965 · tv510380_4.xml · derivative · entry 9 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,890 Underlying: Class A Common Stock · 2,500 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 01:08 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,500 | $32.21 | $80,525.00 |
DisclosureSEC source: 0001144204-19-000965 · tv510380_4.xml · nonDerivative · entry 6 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 01:08 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-19-000965 · tv510380_4.xml · nonDerivative · entry 5 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 01:08 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-000965 · tv510380_4.xml · derivative · entry 8 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,390 Underlying: Class A Common Stock · 2,500 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 01:08 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,500 | $31.30 | $78,250.00 |
DisclosureSEC source: 0001144204-19-000965 · tv510380_4.xml · nonDerivative · entry 4 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 01:08 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-19-000965 · tv510380_4.xml · nonDerivative · entry 3 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 01:08 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-19-000965 · tv510380_4.xml · derivative · entry 7 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,890 Underlying: Class A Common Stock · 2,500 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 01:08 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,500 | $31.72 | $79,300.00 |
DisclosureSEC source: 0001144204-19-000965 · tv510380_4.xml · nonDerivative · entry 2 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 01:08 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 2,500 | $11.83 | $29,575.00 |
DisclosureSEC source: 0001144204-19-000965 · tv510380_4.xml · nonDerivative · entry 1 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| September 12, 2018 Filed Sep 15, 2018 01:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001144204-18-049580 · tv502926_4.xml · derivative · entry 3 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,390 Underlying: Class A Common Stock · 2,500 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
| September 12, 2018 Filed Sep 15, 2018 01:04 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 2,500 | $44.30 | $110,750.00 |
DisclosureSEC source: 0001144204-18-049580 · tv502926_4.xml · nonDerivative · entry 2 Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.